Galectin Therapeutics (NASDAQ:GALT) CFO Sells $22,898.10 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Jack Callicutt sold 3,810 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $6.01, for a total value of $22,898.10. Following the completion of the sale, the chief financial officer directly owned 7,614 shares in the company, valued at approximately $45,760.14. The trade was a 33.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Galectin Therapeutics Trading Down 0.7%

Galectin Therapeutics stock traded down $0.04 on Wednesday, hitting $5.63. 297,514 shares of the stock traded hands, compared to its average volume of 389,706. Galectin Therapeutics Inc. has a 1 year low of $0.73 and a 1 year high of $6.55. The firm has a market cap of $363.02 million, a P/E ratio of -8.80 and a beta of 0.86. The business’s fifty day simple moving average is $4.82 and its 200 day simple moving average is $3.19.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. As a group, analysts predict that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Institutional Trading of Galectin Therapeutics

Several hedge funds have recently bought and sold shares of GALT. Jane Street Group LLC bought a new position in Galectin Therapeutics during the second quarter valued at approximately $1,580,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Galectin Therapeutics during the 1st quarter worth approximately $287,000. Vivaldi Capital Management LP boosted its position in shares of Galectin Therapeutics by 210.0% during the 2nd quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company’s stock valued at $364,000 after acquiring an additional 116,815 shares during the last quarter. Wealthspire Advisors LLC grew its holdings in shares of Galectin Therapeutics by 20.4% in the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock valued at $1,012,000 after purchasing an additional 81,144 shares in the last quarter. Finally, Truist Financial Corp purchased a new position in shares of Galectin Therapeutics in the second quarter valued at $143,000. Institutional investors own 11.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GALT shares. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Galectin Therapeutics in a research report on Thursday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Galectin Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $6.00.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.